Fosun Pharma, medicine Ming Kant again shot! These innovation companies will be in the spotlight by 2020

New Element Almedicine was founded in 2012 and is mainly engaged in the development of innovative drugs for metabolic diseases and anti-cancer drugs, including 7 innovative drugs for the treatment of gout, hyperuric acidemia, non-alcoholic fatty hepatitis (NASH), stomach cancer, bowel cancer and triple-negative breast cancerThe core team of new element medicine, mainly from the United States, has extensive experience in the development of innovative drugs, and its founder, Shi Oriental, has been engaged in the development of innovative first-in-Class drugs such as anti-tumor, anti-HCV and treatment of type 2 diabetes in the United States and the United Kingdom for 20 years before his returnand new element medicine this round of financing of the lead investors Lizhu Pharmaceuticals, Sequoia Capital is also a concernE drug managers combed the discovery that in the past year, Sequoia Capital invested in about 10 biopharmaceutical companies, most of which are innovative drug directionsSequoia Capital's stance of accelerating investment in the pharmaceutical sector has emergedAnother leading investor, Lizhu Pharmaceuticals, as a domestic large-scale integrated pharmaceutical enterprises, in recent years began to accelerate the transformation of innovative pharmaceutical enterprises, not only to increase their own investment in research and development, but also to accelerate the global investment layout, and actively participate in the new drug research and development innovation platform cooperationlast June, Lizhu Pharmaceuticals announced that Cardi Bio, a subsidiary of Lizhu Pharmaceuticals, will contribute 30 million yuan to subscribe for the new registered capital of Sizun Pharmaceuticals of 3.111 million yuan, accounting for 10% of the registered capital of Sizun Pharmaceuticals after the completion of the capital increaseThis outbound investment is intended to give full play to the advantages of research and development, production and commercialization in the cell therapy business, and upon completion of the capital increase, Cardi Bio will conduct a global exclusive global partnership with Sizu Pharmaceuticals for all of its existing product sourcing projects for Vac-T and NK-T cell therapyThis investment is in line with the strategic layout of long-term research and development pipeline in the field of biologic medicine of Lizhu Pharmaceuticalsanother close-up investment took place in October last year, when Livzon International Ventures, a wholly-owned offshore investment platform, invested $33 million in Elicio Therapeutics, along with internationally renowned funds Clal Biotechnology Industries (CBI) and Reliance Capital(New Generation Oncology Immunotechnology Technology, Cambridge, Massachusetts, USA) to advance Elicio's new lymph node-targeted tumor immunotherapy pipeline, including ELI-002, a two-parent KRAS mutant (mKRAS) vaccine (AMPKRAS)Lizhu Pharmaceutical three intensive investment is naturally under the "big hand", but there is "buy" there is "sell", for enterprises, timely replenishment of cash flow has also become the key to enterprise re-empowermentCoincidentally, on the same day that news broke that New Element Pharma had received $30 million in B-round financing, Lizhu Pharmaceuticals announced that it would sell 19.99 percent of Jiangsu Nico for 121.5 million yuan in order to better focus on innovative pharmaceutical majorsE drug managers note that since 2020, a number of pharmaceutical companies have announced selling their sharesOn January 2nd, Yuheng Pharmaceuticals announced that it had agreed to sell its 100% stake in Aono (China) Pharmaceutical Co., Ltdto China Resources 39 Pharmaceutical Co., LtdOn January 6th Haier Bio, a listed company, announced that it would sell its 75% stake in Haimi Kangji Biotech Co., Ltd for 27 million yuan, and that after the completion of the transaction, Haier Bio no longer owns an entity engaged in research and development, production and sales of products related to molecular diagnostics As for the reasons for the sale, Haier Bio said in the announcement, because of the molecular diagnostic POCT has the characteristics of high technical difficulties, development and approval cycle, in the formation of stable income and profit, still need to invest more funds, personnel and management costs, and there is some uncertainty about the development prospects This is to reduce the company's operating risks, better promote the development of the main industry, optimize the industrial layout E drug managers from January to May 2020 in the pharmaceutical industry investment and financing case combing also found that, in addition to Lizhu Pharmaceutical, there are 18 domestic pharmaceutical companies through industrial capital investment innovation-related companies Among them, the face of the many Fosun Pharma, medicine Ming Kang, and most of them as the exclusive investor's identity appeared (Chart source: Hao Yue Capital) side is to withdraw from the investment project, focus on the main industry of innovative pharmaceuticals, on the other hand is to use industrial capital to pursue innovative products, it is clear that in the overall Chinese pharmaceutical industry transformation and upgrading of the background, domestic pharmaceutical companies also began to actively according to their own development needs to actively integrate resources, complete innovation exploration May 16, 2020, Sanyou Bio announced that it received tens of millions of yuan in Round A financing, which was jointly funded by Haier Medical and Jiangbio Founded in 2015 in Shanghai, Sanyou Bio is a high-tech enterprise focused on innovative antibody drug research and development and services, its representative overall projects are CLDN18.2, PD-L1, CD47, CD40, BCMA, IL 17 category of targets of whole human monoclonal antibodies, humanized antibodies, monodomain antibodies, dual-specific antibodies and antibody drug conjugate (ADC), including 2 projects have been confirmed by THE PCC and successfully transferred, there are several projects in the process of animal model verification this round of financing will be used to upgrade the three excellent bio-high-capacity phage display all-human and double-specific antibody library, improve the in vitro drug efficacy drug replacement screening service platform, improve the drug quality research, process research and development and production of cell strain construction service platform, in collaboration with customer incubation nursery project and promote a number of anti-tumor drugs pre-clinical research in the field of CRO, and the three excellent creatures, as well as the industrial capital attention is also the lili biological On May 16, Yan Li Bio completed the latest round of equity financing, which was jointly funded by BRAVE HORSE LIMITED, Oriental Securities and Tyger Pharma Public information shows that, founded in 2008, Lili Bio provides more than 300 international and domestic well-known new drug research and development institutions, including the establishment of pre-clinical drug-effective disease models, testing candidate drug efficacy, testing the biological applicability of medical devices, including a series of international standards of professional research and development outsourcing services As early as the beginning of 2017, when Yanli Bio completed the A-round financing, Tyger Pharmaceuticals was involved in the investment in the field of innovative drugs, Kangfang Bio, Magpie Pharmaceuticals, Yunyun Biology and other innovative enterprises were respectively by Hankang Pharmaceuticals, Cornbey Pharmaceuticals, Broad Pharmaceuticals capital On April 14, , Kangfang Bio completed a pre-IPO $163 million financing for OrbiMed Obo Capital, Fidelity Investments, China Transfer Fund/Restructuring Fund, Boyu Capital, Hankang Pharmaceuticals, Hudson Bay Capital, Qingchi Capital, CRF Investment, AIHC Capital Management it's worth noting that in November, Kangfang Bio announced the completion of nearly $150 million in D-round private placements, making it the sixth-highest-profile funding for a global biotech company in 2019 and the recent landing of Hong Kong stocks kangfang biological has indeed recently received a lot of attention First, the State Drug Administration has accepted the application for the listing of new anti-PD-1 monoanti-drug Pampharian monotomaab (Annikor) jointly developed and commercialized with China Biopharmaceutical Co., Ltd., for the treatment of patients with at least second-line system chemotherapy recurrence or refractive classic Hodgkin's lymphoma, which may become the first listed product after Kangfang BioIPO, and the second is that there are 4 imported PD-1/L1 products and 4 joint ventures/domestic-based talked about industrial capital investment, Fosun Pharma, pharmaceutical Ming Kangding is not around the two enterprises In recent years, the , Medicine Mingkang, has built the ecosystem of biopharmaceutical research and development industry through both endogenous construction and extension mergers and acquisitions, through equity investment, venture capital investment and the formation of joint ventures Investing in innovative pharmaceutical companies with potential has become the norm in the venture capital section, the main investment entities of pharmaceutical Mingkang are the first phase fund established in 2011 and the specially established Yan Cheng Capital in 2015, managing two U.S dollar funds with a total of more than $350 million, and investing in several pharmaceutical companies that have subsequently listed in Baiji Shenzhou February 19, 2020, North Sea Kangcheng announced a $98 million Round D financing, jointly funded by Transatlantic Investment Group and Pharmaming Kant Beihai Kangcheng is a rare leading enterprise in the field of rare disease drugs in China, has a wealth of research and development pipeline, is the sponsor of China's rare disease alliance This investment is related to the focus of the drug Mingkang in the field of rare diseases, after the drug-making organisms and North Sea Kangcheng reached a strategic cooperation agreement to jointly promote the development of rare disease drugs At present, the total shareholding ratio of the fund of the company and the company's shares in Kangcheng in the North Sea is 13.11%, surpassing the company's founder, Xue Qun, to become the largest shareholder and the acquisition of the best Fosun Pharma as early as 2008 determined to lay out macromolecule biopharmaceuticals, has used industrial capital to invest in today's performance is quite bright Fuhong Hanxuan, Fosun Kate In 2020, Fosun Pharma is back in the market, joining Tongde Capital in the investment of Haicheng Pharmaceuticals Haitron Pharmaceuticals was founded in 2013 by Chen Yuanwei, a returning scientist, to develop new drugs for the xenon generation On July 29, 2019, Haitron Pharmaceuticals completed a $40 million B-round financing, jointly funded by Tongde Capital, Fosun Pharmaceuticals, LANXESS Investment, Hengxing Capital, Silicon Valley Torch, etc On January 9, 2020, Haitron Pharmaceuticals continued to complete 32 million U.S dollars of B-round financing, adding B-round investment institutions with Tongde Capital, Fosun Pharmaceuticals, and adding B-round investment institutions such as Strong Ding Capital, Lianlian Health Fund, Jilin Yandong, Guangfa Sinde, etc Haicheng Pharmaceuticals has now realized 8 varieties of new drug product pipeline accumulation, covering a variety of cancers, metabolic diseases and other fields Among them, the new drug HC-1119 for the treatment of prostate cancer has launched a global multicenter Phase III clinical trial, plans to apply for global listing in 2022, and will be developed and produced jointly with the listed company Haicisco subsidiary Of Sichuan Hai Cisco Pharmaceutical Co., Ltd.; In addition to the two "acquaintances" mentioned above, E drug managers noted that the newly listed non-profit biopharmaceutical company Junshi Biowill will invest in mRNA drug research and development enterprise Smicrosine in 2020 Junshi Bio announced on February 6that, according to the development needs of the operation, the company with its own capital of 10,000,000 yuan to participate in the financing of the Micro-Organisms A-round financing and obtained its 2.86 percent equity Micromicros is an early domestic mRNA drug research and development and production of platform-based enterprises, this investment will help the company and Micro-micro-organisms complement each other's advantages, the future cooperation to carry out innovative drugs and innovative combination therapy development, the company's business development has a positive impact according to public information, Smicroshas currently has more than a dozen self-developed mRNA new drug research and development projects, focusing on mRNA personalized cancer vaccine, mRNA infectious disease vaccine, protein defect disease mRNA drugs and genetic disease mRNA drug treatment During the outbreak, Ssa micro-organisms and Tongji University affiliated Oriental Hospital and other emergency development of new coronavirus vaccine, participate in the Ministry of Science and Technology emergency research projects.